K-V's Makena ITC Suit Would Create Monopoly, Pharmacies Say

Law360, New York (November 13, 2012, 2:57 PM EST) -- K-V Pharmaceuticals Co. seeks to establish a monopoly for its premature-birth prevention drug Makena by trying to block pharmacies from importing an ingredient used to produce cheaper versions, an Illinois compounding pharmacy told the U.S. International Trade Commission on Friday.

Alwan Pharmacy and Compounding Center, a proposed respondent to K-V’s ITC complaint that pharmacies in the U.S. are unlawfully importing Makena's active ingredient, 17-hydroxyprogesterone caproate, or HPC, to produce inferior and potentially dangerous versions of the preterm-birth treatment, said the ingredient has been lawfully imported and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.